ESC Congress 2019 with World Congress of Cardiology
VIDEO: Professor Gregory Schwartz on the USA versus European lipid guidelines
read more »
VIDEO: Dr Robert Giugliano discusses the lipid guidelines
read more »
VIDEO: Key messages from the 2019 ESC EAS dyslipidaemia guidelines
read more »
Targeting very high-risk patients for PCSK9 inhibition: more insights from ODYSSEY OUTCOMES
Statin intensity There were further reports from the ODYSSEY OUTCOMES study.1 Dr Rafael Diaz (Cardiology Studies Latin America Rosario, Argentina) and colleagues evaluated the efficacy of alirocumab according to the intensity of baseline statin treatment. Patients were categorised by high intensity statin (88.8%) or low…
read more »
EVOPACS: Evolocumab lowers LDL cholesterol without safety issues in the acute ACS setting
Starting evolocumab in hospital with 1-3 days of an acute coronary syndrome (ACS), substantially lowered LDL cholesterol in the EVOPACS (EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes) Trial (ClinicalTrials.gov Identifier: NCT03287609). This is the first randomised trial of a…
read more »
ESC Congress 2019: Inclisiran marches on with positive results in ORION-11
Inclisiran, a novel siRNA PCSK9 therapeutic, injected twice a year produced potent and durable LDL cholesterol lowering in a high cardiovascular risk population. The safety profile of inclisiran was also favourable, and consistent with that previously reported in the ORION-1 Phase 2 and ORION-3 open-label…
read more »
VIDEO: ORION 11
read more »
VIDEO: EVOPACS evolocumab in the acute ACS setting
read more »
ESC Congress 2019 – News from Poster Sessions: Very low LDL cholesterol in ODYSSEY OUTCOMES appears effective and safe
Acute coronary syndrome (ACS) patients attaining very low LDL cholesterol levels in ODYSSEY OUTCOMES derived at least as much clinical benefit from alirocumab, despite blinded substitution with placebo. There was also no signal for any increase in neurocognitive events, haemorrhagic stroke or new-onset diabetes with…
read more »
ESC Congress 2019 – LDL cholesterol goals go lower…
In the 2019 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines, LDL cholesterol commands the primary position once again.1 This is consistent with overwhelming evidence of the causality of LDL for atherosclerotic cardiovascular disease (ASCVD).2 Much has happened in the clinical trial world since the…
read more »
ESC Congress 2019 – News from Poster Sessions: Real-world use of evolocumab in FH patients
In the largest cohort to date of patients with familial hypercholesterolaemia (FH, inherited high cholesterol) treated with a PCSK9 inhibitor in real-world practice, evolocumab was shown to be efficacious and well tolerated. This was a multicentre, observational study in 10 European countries. A total of…
read more »
VIDEO: 2019 ESC EAS Dyslipidaemia Guidelines
read more »
VIDEO: Very low LDL C levels in ODYSSEY OUTCOMES
read more »
